PLX Protalix BioTherapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NYSEAMERICAN: PLX
- PE Ratio
As of May 13, 2025, the Protalix BioTherapeutics stock's PE ratio is 33.2. This takes into account the latest EPS of $0.05 and stock price of $1.66.
PLX PE ratio history
The PE ratio of Protalix BioTherapeutics has averaged 16.29 over the last ten years. The current price-to-earnings ratio of 33.2 is 104% more than the historical average. Analyzing the last ten years, PLX's PE ratio reached its highest point in the Mar 2025 quarter at 51.2, when the price was $2.56 and the EPS was $0.05. The lowest point was recorded in the Sep 2016 quarter, when it reached 1.14 with a price of $5.7 and an EPS of $5.
Protalix BioTherapeutics PE ratio by year
Maximum annual increase: 216.93% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 47 | 216.93% | $1.88 | $0.04 |
| 2023 | 14.83 | N/A | $1.78 | $0.12 |
| 2022 | N/A | N/A | $1.37 | -$0.31 |
| 2021 | N/A | N/A | $0.83 | -$0.62 |
| 2020 | N/A | N/A | $3.63 | -$0.22 |
| 2019 | N/A | N/A | $3.28 | -$1.23 |
| 2018 | N/A | N/A | $3.11 | -$1.8 |
| 2017 | N/A | N/A | $6.61 | -$6.37 |
| 2016 | N/A | N/A | $4.45 | -$2.9 |
| 2015 | 1.67 | N/A | $10.2 | $6.1 |
| 2014 | N/A | N/A | $18.4 | -$3.2 |
| 2013 | N/A | N/A | $38.9 | -$3 |
| 2012 | N/A | N/A | $51.9 | -$1.3 |
| 2011 | N/A | N/A | $49.3 | -$4.3 |
| 2010 | N/A | N/A | $99.8 | -$3.6 |
Protalix BioTherapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 51.2 | 8.94% | $2.56 | $0.05 |
| Dec 2024 | 47 | N/A | $1.88 | $0.04 |
| Sep 2024 | N/A | N/A | $1.02 | -$0.15 |
| Jun 2024 | N/A | N/A | $1.17 | -$0.22 |
| Mar 2024 | 12.6 | -15.04% | $1.26 | $0.1 |
| Dec 2023 | 14.83 | 25.04% | $1.78 | $0.12 |
| Sep 2023 | 11.86 | -40.7% | $1.66 | $0.14 |
| Jun 2023 | 20 | N/A | $2 | $0.1 |
| Mar 2023 | N/A | N/A | $2.1 | -$0.3 |
| Dec 2022 | N/A | N/A | $1.37 | -$0.31 |
| Sep 2022 | N/A | N/A | $1.04 | -$0.37 |
| Jun 2022 | N/A | N/A | $1.09 | -$0.39 |
| Mar 2022 | N/A | N/A | $1.06 | -$0.53 |
| Dec 2021 | N/A | N/A | $0.83 | -$0.62 |
| Sep 2021 | N/A | N/A | $1.33 | -$0.45 |
PLX Price vs fair value
PLX average PE ratio chart
The current PE ratio of PLX is above its 3, 5 and 10-year averages.
PLX PE vs peers
When compared to its peer NBIX, PLX's PE ratio is lower, but it is higher than PFE's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PFE Pfizer Inc | 15.83 | $125.13B |
| PLX Protalix BioTherapeutics Inc | 33.4 | $132.94M |
| NBIX Neurocrine Biosciences Inc | 38.44 | $11.53B |
| FOLD Amicus Therapeutics Inc | N/A | $1.81B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $19.37B |
Frequently asked questions
What is Protalix BioTherapeutics's PE ratio?
As of May 13, 2025, PLX stock has a price to earnings ratio of 33.2.
What is the 3-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 3 years, the average PE ratio for PLX stock is 26.25.
What is the 5-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 5 years, the average PE ratio for PLX stock is 26.25.
What is the highest PE ratio for PLX?
Over the last ten years, the quarterly PE ratio reached its highest level at 51.2 in the Mar 2025 quarter.
How does the current PE ratio for PLX compare to its historical average?
PLX's price to earnings ratio is currently 104% above its 10-year historical average.
How is PLX's PE ratio calculated (Protalix BioTherapeutics PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (May 13, 2025), Protalix BioTherapeutics's share price is $1.66. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $0.05. Therefore, Protalix BioTherapeutics's price to earnings ratio for today is 33.2. PE RATIO(33.2) = STOCK PRICE($1.66) / TTM EPS($0.05)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.